Journal ArticleDOI
Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants.
Paolo Prandoni,Walter Ageno,Nicola Mumoli,Nello Zanatta,Davide Imberti,Adriana Visonà,Maurizio Ciammaichella,Livio Simioni,Roberto Cappelli,Eugenio Bucherini,Marcello Di Nisio,Giampiero Avruscio,Giuseppe Camporese,Roberto Parisi,S. Cuppini,Giacomo Turatti,Franco Noventa,Lucia Sarolo +17 more
TLDR
In patients with proximal DVT treated with the DOACs, the persistence of ultrasound detectable RVT is likely to occur less frequently than in patients treated with conventional anticoagulation.About:
This article is published in Thrombosis Research.The article was published on 2017-05-01. It has received 27 citations till now. The article focuses on the topics: Venous thrombosis.read more
Citations
More filters
Journal ArticleDOI
ERS statement on chronic thromboembolic pulmonary hypertension
Marion Delcroix,Adam Torbicki,Deepa Gopalan,Olivier Sitbon,Frederikus A. Klok,Irene Lang,David J. Jenkins,Nick H. Kim,Marc Humbert,Xavier Jaïs,Anton Vonk Noordegraaf,Joanna Pepke-Zaba,Philippe Brenot,Peter Dorfmüller,Peter Dorfmüller,Elie Fadel,Hossein Ardeschir Ghofrani,Hossein Ardeschir Ghofrani,Marius M. Hoeper,Pavel Jansa,Michael M. Madani,Hiromi Matsubara,Takeshi Ogo,Ekkehard Grünig,Andrea Maria D'Armini,Nazzareno Galiè,Bernhard C. Meyer,Patrick Corkery,Gergely Meszaros,Eckhard Mayer,Gérald Simonneau +30 more
TL;DR: A review of the literature and current practice concerning diagnosis and management of chronic thromboembolic pulmonary hypertension (CTEPH) is presented in this article, which is a rare complication of acute pulmonary embolism, either symptomatic or not.
Journal ArticleDOI
Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis.
Elisa D'Alessandro,Christian Becker,Wolfgang Bergmeier,Christoph Bode,Joshua H. Bourne,Helena Brown,Harry R. Büller,Arina J. ten Cate-Hoek,Vincent ten Cate,Yvonne J. M. van Cauteren,Yam F. H. Cheung,Audrey C. A. Cleuren,Daniëlle Coenen,Harry J.G.M. Crijns,Ilaria De Simone,Sophie Dólleman,Christine Espinola Klein,Delia I. Fernandez,Lianne Granneman,Arnoud W J van 't Hof,Peter K. Henke,Yvonne M. C. Henskens,Jingnan Huang,Lisa K. Jennings,Natalie J Jooss,Mieke F.A. Karel,Danique L. van den Kerkhof,Frederik A. Klok,Bram Kremers,Bernhard Lämmle,Avi Leader,Avi Leader,Annika Lundström,Nigel Mackman,Pier Mannuccio Mannucci,Zahra Maqsood,Paola E. J. van der Meijden,Marc van Moorsel,Luis A. Morán,John Morser,Manouk J.W. van Mourik,Stefano Navarro,Raluca A. I. Neagoe,Renske H. Olie,Pauline C. S. van Paridon,Jens Posma,Isabella Provenzale,Pieter H. Reitsma,Billy Scaf,Leon J. Schurgers,Jaap Seelig,Agneta Siegbahn,Bob Siegerink,Oliver Soehnlein,Eva Maria Soriano,Marcin A. Sowa,Henri M. H. Spronk,Robert F. Storey,Chukiat Tantiwong,Alicia Veninga,Xueqing Wang,Steve P. Watson,Jeff Weitz,Sacha Zeerleder,Hugo ten Cate +64 more
TL;DR: A state-of-the-art reflection of expert opinions and consensus recommendations regarding the following topics are presented: challenges of the endothelial cell barrier, circulating cells and thrombo-inflammation, focused on platelets, neutrophils, and neutrophil extracellular traps.
Journal ArticleDOI
Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome.
Kristin Kornelia Utne,Anders E.A. Dahm,Hilde Skuterud Wik,Lars-Petter Jelsness-Jørgensen,Per Morten Sandset,Waleed Ghanima +5 more
TL;DR: Patients treated with rivaroxaban had lower rate of PTS and better HRQoL after DVT compared to patients treated with warfarin, however, these results should be interpreted with caution due to the limitation imposed by study design.
Journal ArticleDOI
Rivaroxaban in the treatment of upper extremity deep vein thrombosis: A single-center experience and review of the literature.
Ilya Schastlivtsev,Kirill Lobastov,Sergey Tsaplin,Irina Kanzafarova,Victor Barinov,Leonid Laberko,Rodoman Gv,Sergey Zhuravlev +7 more
TL;DR: Treatment of UEDVT with rivaroxaban, preceded by one to two days of LMWH, seems to be safe and effective.
Journal ArticleDOI
Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study.
Elena Campello,Luca Spiezia,Chiara Simion,Daniela Tormene,Giuseppe Camporese,Fabio Dalla Valle,Anna Poretto,Cristiana Bulato,Sabrina Gavasso,Claudia M. Radu,Paolo Simioni +10 more
TL;DR: DOACs and heparin/vitamin K antagonists showed a similar efficacy in treating VTE in patients with thrombophilia and the use of DOACs was associated with a lower 2‐year risk of VTE recurrence after anticoagulant discontinuation.
References
More filters
Journal ArticleDOI
The long-term clinical course of acute deep venous thrombosis.
Paolo Prandoni,Anthonie W. A. Lensing,Alberto Cogo,S. Cuppini,Sabina Villalta,Mariarosa Carta,Anna M. Cattelan,P. Polistena,Enrico Bernardi,Martin H. Prins +9 more
TL;DR: The clinical course of a first episode of symptomatic deep venous thrombosis in a large consecutive series of patients who had long-term follow-up was assessed and the potential risk factors for these three outcomes were evaluated.
Journal ArticleDOI
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
Clive Kearon,Michael Gent,Michael Gent,Jack Hirsh,Jack Hirsh,Jeffrey I. Weitz,Michael J. Kovacs,David Anderson,Alexander G.G. Turpie,Alexander G.G. Turpie,David Green,Jeffrey S. Ginsberg,Jeffrey S. Ginsberg,Philip S. Wells,Betsy MacKinnon,Betsy MacKinnon,Jim A. Julian +16 more
TL;DR: Patients with a first episode of idiopathic venous thromboembolism should be treated with anticoagulant agents for longer than three months, according to a prespecified interim analysis of efficacy.
Journal ArticleDOI
A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism
Sam Schulman,Ann-Sofie Rhedin,Per Lindmarker,A. Carlsson,G Lärfars,Nicol P,Enno Loogna,Else Svensson,Bengt Ljungberg,Hans Walter,Stanka Viering,S Nordlander,Barbro Leijd,Kjell-Ake Jonsson,Martin Hjorth,Olle Linder,Jonas Boberg +16 more
TL;DR: A multicenter trial comparing six weeks of oral anticoagulant treatment with six months of such therapy in patients who had a first episode of venous thromboembolism, which confirmed the initial diagnoses of deep-vein thromboses and pulmonary embolism.
Journal ArticleDOI
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients
Paolo Prandoni,Franco Noventa,Angelo Ghirarduzzi,Vittorio Pengo,Enrico Bernardi,Raffaele Pesavento,Matteo Iotti,Daniela Tormene,Paolo Simioni,Antonio Pagnan +9 more
TL;DR: Besides unprovoked presentation, other factors independently associated with a statistically significant increased risk of recurrent VTE are thrombophilia, clinical presentation with primary DVT, shorter duration of anticoagulation, and increasing age.
Journal ArticleDOI
Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study
TL;DR: In unselected patients who have had a first episode of venous thromboembolism, testing for heritable thrombophilia does not allow prediction of recurrent VTE in the first 2 years after anticoagulant therapy is stopped, however, assessment of clinical risk factors associated with the firstepisode of VTE does predict risk of recurrence.